News and Media

February 23, 2011: Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens

December 14, 2010: Licensee Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine

July 12, 2010: Immunotope and Midatech Form Joint Venture, Syntara LLC, for the Development of Immune Therapies

March 29, 2010: Licensee Begins Patient Recruitment for Phase I Trial of DPX-0907 Cancer Vaccine

December 9, 2009: Licensee Receives Clearance from FDA to Proceed with Phase 1 Clinical Trial for its Therapeutic Cancer Vaccine

July 14, 2009: ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens

May 23, 2008: ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PA's Best 50 Women in Business

December 10, 2007:  ImmunoVaccine Technologies, Inc. to Acquire Immunotope Inc. 

June 26, 2007: Immunotope, Inc. Receives Second Investment from Ben Franklin Technology Partners of Southeastern PA  $350,000 in additional funding for Phase I clinical trial in ovarian and breast cancer

June 5, 2007: Immunotope, Inc. Receives NIAID Grant Funding for Dengue Virus Vaccine Development

April 2007 Immunotope:  New Vaccine Stops Cancer Cells from Reproducing

March 2, 2007: Immunotope, Inc.  Announces Board and Management Appointments  Company names two new directors and interim CEO

October 20, 2006: Immunotope Inc. Awarded a US Army Phase II SBIR Contract to Develop a Prostate Cancer Early Detection Test  $780,000 contract will develop a sensitive, noninvasive autoantibody biomarker test  

August 19, 2005: Immunotope OCPM Vaccine to be Evaluated in Phase I Ovarian Cancer Immunotherapy Clinical Trial